Less than four months later, the European Medicines Agency recommends marketing authorization for lecanemab for the treatment of Alzheimer’s disease.
The news that many people have been waiting for has finally arrived. The European Medicines Agency (EMA) now has the green light to begin the approval process of one of the drugs that can revolutionize the treatment of Alzheimer’s disease: Leqembi
Session limit reached
- Access to Premium content is open courtesy of the establishment you are in, but right now there are too many users logged in at once. Please try again after a few minutes.
try again
You have exceeded the session limit
- You can only have three sessions started at a time. We have closed the oldest session so you can continue browsing the rest without limits.
Keep browsing
Article for subscribers only
Report a bug
#Europe #reviews #decision #decides #approve #lecanemab #Alzheimers
